絞り込み

16548

広告

スターを付ける スターを付ける     (50view , 0users)

Full Text Sources

Intravenous imiglucerase enzyme replacement therapy for Gaucher disease type 1 administered every 2 weeks is at variance with the imiglucerase plasma half-life of a few minutes. We hypothesized that studying the pharmacokinetics of imiglucerase in blood Gaucher disease type 1 monocytes would be more relevant for understanding enzyme replacement therapy responses.
PMID: 30128966 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード